J&J presents new data for TAR-200 intravesical delivery system

US healthcare giant Johnson & Johnson (NYSE: JNJ) has shared new findings for TAR-200, an intravesical gemcitabine releasing system, for patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).

TAR-200 is inserted directly into the bladder in a brief outpatient procedure, without the need for anesthesia or sedation.

Two data cuts from Cohort 2 and Cohort 4 of the Phase IIb SunRISe-1 study were featured in the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology plenary session at the 2025 American Urological Association (AUA) Annual Meeting, with findings representing the highest overall complete response rate for a monotherapy treatment observed for patients with this type of bladder cancer, along with the longest duration of response for monotherapy treatment., the company noted.